DuP-697 (0-100 nM; 24 hours; HT29 cells) treatment shows antiproliferative with an IC ₅₀ value of 42.8 nM.
DuP-697 (25-100 nM; 72 hours; HT29 cells) treatment causes concentration dependent apoptosis in HT29 cells. The percentage of UR (apoptosis portion) area increases gradually according to the concentration of DuP-697 from 7% in control group to 52% in 100 nM DuP-697.
DuP-697 in 100, 10 and 1 nM concentrations cause antiangiogenic effect. Antiangiogenic scores of DuP-697 are 1.2, 0.8 and 0.5, respectively.

DuP-697 is a potent inhibitor of paw swelling in nonestablished and established adjuvant arthritis in rats (ED ₅₀ = 0.03 and 0.18 mg/kg/day, respectively). DuP-697 has no effect on phenylquinone writhing in rats (ED ₅₀ greater than 100 mg/kg), but is analgetic against inflammation-related pain in the Randall-Selitto assay (ED ₅₀ = 3.5 mg/kg) and is a very potent antipyretic agent (ED ₅₀ = 0.05 mg/kg). DuP-697 (5 mg/kg i.v.) does not alter renal blood flow or the renal vascular response to angiotensin II in furosemide-pretreated, volume-depleted rats.
DuP-697 is a moderate inhibitor of bull seminal vesicle prostaglandin (PG) synthesis (IC ₅₀ of 24 μM) and a potent inhibitor of rat brain PG synthesis (IC ₅₀ of 4.5 μM) but was ineffective against rat kidney PG synthesis (IC ₅₀ of 75 μM).